Filing Details

Accession Number:
0001144204-17-034725
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-06-28 21:10:12
Reporting Period:
2017-06-26
Filing Date:
2017-06-28
Accepted Time:
2017-06-28 21:10:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1607962 Rewalk Robotics Ltd. RWLK Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1661229 Jeff Dykan C/O Rewalk Robotics, Ltd.
3 Hatnufa St. P.o. Box 161
Yokneam Ilit L3 20692203
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares, Par Value Nis 0.01 Per Share Disposition 2017-06-26 37,030 $3.00 1,550,070 No 4 S Indirect By partnership
Ordinary Shares, Par Value Nis 0.01 Per Share Disposition 2017-06-27 49,970 $3.09 1,500,100 No 4 S Indirect By partnership
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By partnership
No 4 S Indirect By partnership
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Ordinary Shares, Par Value Nis 0.01 Per Share 6,022 Indirect ESOP
Footnotes
  1. Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 15, 2016.
  2. The disposed of securities consist of 27,759 Ordinary Shares sold by SCP Vitalife Partners II, L.P. ("SCP Vitalife") and 9,271 shares sold by SCP Vitalife Partners (Israel) II, L.P. ("SCP Vitalife Israel").
  3. The Reporting Person is a director of SCP Vitalife II GP, Ltd. ("SCP Vitalife GP"), which is the sole general partner of SCP Vitalife II Associates, L.P. ("SCP Vitalife Associates"). SCP Vitalife Associates is the sole general partner of each of SCP Vitalife and SCP Vitalife Israel, the direct beneficial owner of the Ordinary Shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of the Ordinary Shares held by SCP Vitalife and SCP Vitalife Israel, except to the extent of his pecuniary interest therein.
  4. The disposed of securities consist of 37,459 Ordinary Shares sold by SCP Vitalife and 12,511 shares sold by SCP Vitalife Israel.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.0000 to $3.2000, inclusive. The reporting person undertakes to provide to ReWalk Robotics, Ltd. ("ReWalk"), any security holder of ReWalk, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4.
  6. As of June 27, 2017, SCP Vitalife Associates, as the general partner of SCP Vitalife and SCP Vitalife Israel, may be deemed to beneficially own 1,357,574 Ordinary Shares, which consist of 1,017,674 and 339,900 Ordinary Shares held by SCP Vitalife and SCP Vitalife Israel, respectively. SCP Vitalife GP is the general partner of SCP Vitalife Associates and, as such, shares voting and dispositive power over, and may be deemed to beneficially own, the Ordinary Shares held by the foregoing entities. The Reporting Person shares voting and dispositive power over, and may be deemed to beneficially own 1,500,100 Ordinary Shares, which consist of the Ordinary Shares as set forth in footnote (7) to this Form 4.
  7. As of June 27, 2017, consists of 1,357,574 Ordinary Shares held by the foregoing entities due to the Reporting Person serving as a director of SCP Vitalife GP, as well as (i) 62,006 Ordinary Shares held by Vitalife Partners (Overseas) L.P., (ii) 20,506 Ordinary Shares held by Vitalife Partners (Israel) L.P., (iii) 20,733 Ordinary Shares held by Vitalife Partners (D.C.M) L.P. ("Vitalife Partners DCM", and together with Vitalife Partners (Overseas) L.P. and Vitalife Partners (Israel) L.P., the "Vitalife I Entities") and (iv) 39,281 Ordinary Shares currently held by the Office of the Chief Scientist of the State of Israel ("OCS"), that the Vitalife I Entities have the right to acquire from the OCS, due to the Reporting Person serving as a director of Vitalife Life Sciences Ltd., the general partner of Vitalife Partners Management L.P., which is the general partner of each of the Vitalife I Entities.
  8. Represents 6,022 Ordinary Shares issuable upon the vesting of restricted stock units ("RSUs") granted on December 15, 2014 under the ReWalk 2014 Equity Incentive Plan. One-third, or 2,007 Ordinary Shares, of the RSUs vested on the first anniversary of the date of grant and the remaining RSUs vest in equal quarterly installments of 501 Ordinary Shares each starting one quarter after the first anniversary of the date of grant.